Business Context and Reporting Period
This Form 8-K Current Report was filed by Eli Lilly and Company on November 18, 2025. The report discloses a corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the election of a new director to the Board of Directors.
Guidance, Outlook, and Management Commentary
The Board elected Dr. Carolyn R. Bertozzi as a new member, effective December 8, 2025. Dr. Bertozzi, 59, is a Professor at Stanford University and an Investigator at the Howard Hughes Medical Institute. She will serve on the Science and Technology Committee and the Ethics and Compliance Committee. The Board determined she is independent under NYSE standards. She will stand for shareholder election at the annual meeting in May 2026 and will participate in the standard director compensation program.
Key Facts for Investor Verification
- Dr. Carolyn R. Bertozzi was elected to the Board effective December 8, 2025.
- She will serve on the Science and Technology and Ethics and Compliance Committees.
- She is classified as an independent director.
- She will stand for election by shareholders in May 2026.
- No financial data or guidance is included in this specific filing.